The Booming Business of Compounded Weight-Loss Drugs Faces Scrutiny
As telehealth providers increasingly offer compounded versions of popular weight-loss medications, concerns grow about regulation, safety, and the definition of legal drug compounding.
Compounding pharmacies, which prepare customized medications, are experiencing a boom, largely driven by the demand for weight-loss drugs like semaglutide and tirzepatide. These pharmacies are partnering with telehealth sites to offer cheaper alternatives to brand-name GLP-1 medications such as Ozempic and Zepbound. However, this surge in compounded drugs is drawing scrutiny from drug manufacturers and patient advocates concerned about regulatory oversight and patient safety.
Diane Kinkade, a patient who sought weight-loss medication, found a telehealth provider that prescribed a compounded version of tirzepatide. While initially successful, she later experienced severe side effects after the telehealth service switched compounding pharmacies. This experience highlights a potential risk for patients who rely on these compounded medications.
Eli Lilly, the maker of Zepbound, has publicly stated that it is the sole lawful supplier of FDA-approved tirzepatide and that compounded versions are not FDA-approved products. The company has pursued legal action against compounding pharmacies, arguing they are unlawfully mass-producing "knockoff drugs."
What Are Compounding Pharmacies?
Compounding pharmacies have a long history of preparing personalized medications for patients. Traditionally, pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act prepare small batches of medication for individual patients with a prescription. These pharmacies are regulated by state boards of pharmacy and are not subject to the same stringent FDA regulations, such as current good manufacturing practices, as large-scale drug manufacturers. They are expected to follow United States Pharmacopeia (USP) guidelines and source active ingredients from FDA-registered suppliers.
In response to events like the 2012 meningitis outbreak linked to a compounding pharmacy, Congress created a new category in 2013: outsourcing facilities, known as 503Bs. These facilities are more tightly regulated, must adhere to current good manufacturing practices, and are subject to FDA inspections. They can produce drugs in larger quantities, often to address national shortages or when manufacturers discontinue a drug, and can do so without an individual prescription for each batch.
Regulatory Challenges and Growth Drivers
The demand for GLP-1 drugs, which outstripped supply soon after their release, created an opportunity for compounding pharmacies. Initially, 503A pharmacies were approached by prescribers seeking compounded versions for patients facing shortages or high costs. As the trend grew, telehealth sites began advertising these cheaper compounded options, making them more accessible to consumers.
The financial struggles of many traditional pharmacies, exacerbated by low reimbursement rates from pharmacy benefit managers (PBMs), have made compounding a vital revenue stream. Compounded drugs are typically paid for in cash by consumers, bypassing the PBM system and offering a profitable alternative for pharmacies.
Legality and Safety Concerns
Compounding pharmacies often differentiate their products from brand-name drugs by adding other ingredients, such as vitamin B12, or by altering the dosage formulation. The FDA has clarified its policies, stating that a compounded drug is considered a copy if it contains the same active pharmaceutical ingredient in a similar or easily substitutable strength and can be used via the same route of administration as the commercially available product. The agency has begun issuing warning letters to compounding pharmacies for violations related to making copies of FDA-approved GLP-1 drugs.
Research has suggested that patients using compounded GLP-1s may experience more adverse side effects compared to those using brand-name products, including nausea, diarrhea, and abdominal pain. There have also been reports of prescribing and preparation errors. While some compounding pharmacies emphasize their quality control measures and adherence to sourcing regulations, others are criticized for operating in a less transparent manner.
The legal landscape for compounding pharmacies is complex, with manufacturers hesitant to pursue expensive patent infringement lawsuits against numerous individual compounding pharmacies. This has allowed the practice of compounding GLP-1s to continue, even as regulatory bodies and drugmakers express concerns about patient safety and the integrity of the pharmaceutical supply chain.